🫀 VESALIUS-CV: Why Does This Trial Matter? Most PCSK9 inhibitor outcomes data has come from secondary prevention: patients who already had an MI, stroke, or major cardiovascular event. VESALIUS-CV asked a different question: can we prevent that first event? More than 12,000 high-risk patients with atherosclerosis or high-risk diabetes, but no prior MI or stroke, were randomized to evolocumab or placebo. Over a median 4.6 years: 📊 12,257 patients enrolled 📊 No prior MI or stroke 📉 25% relative risk reduction in CHD death, MI, or ischemic stroke (3-point MACE) 📉 19% relative risk reduction in the broader 4-component CV endpoint (4-point MACE) This shifts the paradigm: we now have randomized outcomes evidence supporting intensive LDL-C lowering with evolocumab before a first major cardiovascular event in appropriately selected high-risk patients. Prevent the first MI or stroke, not just the next one. 🎥 Watch the full breakdown in our latest reel. Featuring Anurag Mehta, MD, FASPC, Asst. Professor of Medicine, Cardiology, Emory University @amehta_09 Supported by an educational grant from @Amgen. ASPC maintains full editorial oversight and approval of program content. Learn more here: aspconline.org/pcsk9-educati… #VESALIUSCV #PCSK9 #PreventiveCardiology #CardiovascularHealth #LDLC #CVPrevention #MedEd #Evolocumab